Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by Barclays PLC

Barclays PLC lessened its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 26.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 162,772 shares of the company’s stock after selling 59,019 shares during the period. Barclays PLC’s holdings in Bausch Health Companies were worth $1,327,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BHC. Goldentree Asset Management LP increased its holdings in Bausch Health Companies by 31.0% in the third quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock valued at $239,552,000 after buying an additional 6,958,717 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Bausch Health Companies by 234.0% in the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock worth $31,598,000 after acquiring an additional 2,685,675 shares during the period. Maple Rock Capital Partners Inc. purchased a new position in Bausch Health Companies in the 3rd quarter valued at approximately $16,850,000. Mackenzie Financial Corp raised its holdings in Bausch Health Companies by 111.0% during the second quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after purchasing an additional 1,252,834 shares during the last quarter. Finally, Clearline Capital LP purchased a new stake in Bausch Health Companies during the second quarter worth $6,881,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Trading Up 0.5 %

Bausch Health Companies stock opened at $7.65 on Friday. The stock has a 50 day moving average of $8.25 and a 200-day moving average of $7.32. The stock has a market cap of $2.77 billion, a P/E ratio of -15.94 and a beta of 0.69. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the business earned $1.03 EPS. The business’s quarterly revenue was up 12.2% on a year-over-year basis. As a group, equities analysts predict that Bausch Health Companies Inc. will post 3.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BHC has been the subject of a number of analyst reports. Royal Bank of Canada boosted their price target on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Finally, Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Bausch Health Companies currently has a consensus rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.